Competitive Exams: Pharmacy MCQs (Practice-Test 29 of 29)

  1. To formulate a pressurized metered-dose inhaler (pmdi), the formulation scientist has following options for delivering an nce

    1. powder

    2. suspension

    3. solution

    4. all of the above

  2. The evaluation, optimization and control of flow and dispersion (deagregation) characteristics of the formulation are critical in case of

    1. pressurized metered-dose inhaler

    2. dry powder inhalers

    3. nebulizers

    4. all the three

  3. Which of the following is bacterial toxin?

    1. phospholipase a − 1

    2. phonolipin a − 2

    3. atrospholipase c

    4. phospholipase d

  4. Hormones that increase cholesterol synthesis is

    1. insulin

    2. glucagon

    3. thyroxin

    4. glucocorticoid

  5. Which of the following is not isosteric group of-ch

    1. -ch2

    2. -nh

    3. -oh

    4. = n

  6. In the DNA structure, the groove appears at every

    1. 2.5 a0

    2. 3.4 a0

    3. 2 a0

    4. 5.5 a0

  7. The active species in ‘fries re-arrangement’ is

    1. anion

    2. cation

    3. free radical

    4. all of the above

  8. Papulocardins and echinocardins have potential antifungal property. They

    1. inhibit a-glycan synthetase non-competetively

    2. inhibit chitin synthase competitively

    3. bind to mannoproteins

    4. inhibit ipc synthase

  9. Normally polymer drug conjugates achieve tumor-specific targeting because of the epr. Epr means

    1. endo plasmic reticulum

    2. effective permeation rate

    3. enhanced permeation and retention

    4. electro plate retention

  10. The latest antifungal agent is

    1. amphotericin b

    2. voriconazole

    3. fluconazole

    4. griseofulvin